Athenex, Inc. (60)

Browse by Contract Category

Contracts

Sixth Amendment to Credit and Guaranty Agreement, by and among Athenex, Inc., the Lenders party thereto, and Oaktree Fund Administration, LLC, as administrative agent for the... (Filed With SEC on August 18, 2022)
Second Amended and Restated Exclusive License and Option Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated October 12, 2021 (Filed With SEC on March 16, 2022)
Second Amended and Restated Co-Development Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated October 12, 2021 (Filed With SEC on March 16, 2022)
Employment Agreement between the Company and Joe Annoni, effective as of February 18, 2022 (Filed With SEC on February 22, 2022)
Sales Agreement, dated August 20, 2021, by and between the Company and SVB Leerink LLC as sales agent (Filed With SEC on August 20, 2021)
Agreement and Plan of Merger, by and among Athenex, Inc., Athenex Pharmaceuticals LLC, Kuur Therapeutics, Inc., the holders of the shares of Series C Preferred Stock or Series C-1... (Filed With SEC on May 5, 2021)
Limited Waiver under Revenue Interest Purchase Agreement, by and among ATNX SPV, LLC, Athenex, Inc., and the Purchaser parties thereto, dated as of August 14, 2022 (Filed With SEC on August 18, 2022)
Form of Pre-Funded Warrant (Filed With SEC on August 15, 2022)
Underwriting Agreement, dated August 10, 2022, by and between the Company and SVB Securities LLC (Filed With SEC on August 15, 2022)
Form of Salary Deduction and Stock Purchase Agreement (Filed With SEC on March 29, 2022)
Third Amendment to Credit and Guaranty Agreement and First Amendment to the Warrants between Athenex and Oaktree, dated January 19, 2022 (Filed With SEC on March 16, 2022)
Second Amendment to Credit and Guaranty Agreement between Athenex and Oaktree, dated December 14, 2021 (Filed With SEC on March 16, 2022)
Third Supplemental Agreement and Amendment to License Agreement by and among Athenex, Inc. and Chongqinq Guangzhou Xiangxue Pharmaceutical Co., Ltd., dated November 8, 2021 (Filed With SEC on March 16, 2022)
First Supplemental Agreement to License Agreement by and among Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd. and Guangzhou Xiangxue Pharmaceutical Co., Ltd., dated... (Filed With SEC on March 16, 2022)
Purchase Agreement, by and between Athenex, Inc. and ImmunityBio, Inc. dated January 7, 2022 (Filed With SEC on January 12, 2022)
Consulting Agreement, dated as of January 1, 2022 between Athenex, Inc. and Simon Pedder (Filed With SEC on December 28, 2021)
Consulting Agreement, dated September 1, 2021, between Athenex, Inc. and Randoll Sze (Filed With SEC on September 3, 2021)
Amended and Restated Exclusive License and Option Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated February 28, 2020 (Filed With SEC on August 5, 2021)
Amended and Restated Co-Development Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated February 28, 2020 (Filed With SEC on August 5, 2021)
First Amendment and Limited Waiver to Credit and Guaranty Agreement between Athenex and Oaktree, dated June 3, 2021 (Filed With SEC on August 5, 2021)
Second Amendment to License Agreement dated as of February 15, 2021 by and between Athenex, Inc. and PharmaEssentia Corp (Filed With SEC on May 6, 2021)
Lock-Up Agreement between Athenex, Inc. and each of the parties named therein, dated as of May 4, 2021 (Filed With SEC on May 5, 2021)
Lock-Up Agreement between Athenex, Inc. and Touchstone Innovations Businesses LLP (IP Group), dated May 4, 2021 (Filed With SEC on May 5, 2021)
Manufacture and Supply Agreement dated as of January 15, 2021 by and between Athenex Pharmaceutical Division, LLC and Ingenus Pharmaceuticals, LLC (Filed With SEC on March 1, 2021)
Co-Marketing, Manufacture and Supply Agreement dated as of November 2, 2020 by and between Athenex Pharmaceutical Division, LLC and Ingenus Pharmaceuticals, LLC (Filed With SEC on March 1, 2021)
Asset Purchase and Sale Agreement dated as of September 1, 2020 by and between Athenex Pharmaceutical Division, LLC and Ingenus Pharmaceuticals, LLC (Filed With SEC on March 1, 2021)
Form of Restricted Stock Award Agreement pursuant to the 2017 Omnibus Incentive Plan (Filed With SEC on March 1, 2021)
Intercreditor Agreement dated as of August 4, 2020, by and among Oaktree Fund Administration, LLC, as administrative agent, and Sagard Healthcare Royalty Partners, LP, and as... (Filed With SEC on November 5, 2020)
Assignment and Assumption dated as of August 4, 2020, by and among Athenex, Inc, as the borrower, Sagard Healthcare Royalty Partners, LP, OPB SHRP Co-Invest Credit Limited and... (Filed With SEC on November 5, 2020)
Security Agreement dated as of August 4, 2020, by and between Athenex, Inc. and Sagard Healthcare Royalty Partners, LP (Filed With SEC on November 5, 2020)
Underwriting Agreement, dated September 9, 2020, by and between the Company and SVB Leerink LLC, RBC Capital Markets, LLC and Evercore Group L.L.C., as representatives of the... (Filed With SEC on September 10, 2020)
Revenue Interest Financing Agreement (Filed With SEC on August 6, 2020)
Form of Warrant to Purchase Common Stock (Filed With SEC on August 6, 2020)
Second Supplemental Agreement to License Agreement dated December 12, 2019 by and among Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd. and Guangzhou Xiangxue... (Filed With SEC on August 6, 2020)
Amended and Restated 2017 Omnibus Incentive Plan (Filed With SEC on August 6, 2020)
Registration Rights Agreement by and among Athenex, Inc. and the purchasers named therein, dated as of June 19, 2020 (Filed With SEC on August 6, 2020)
Security Agreement dated as of June 19, 2020, by and among Athenex, Inc., the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto,... (Filed With SEC on August 6, 2020)
Credit Agreement and Guaranty dated as of June 19, 2020, by and among Athenex, Inc., the subsidiary guarantors from time to time party thereto, the lenders from time to time party... (Filed With SEC on June 22, 2020)
Form of Warrant to Purchase Common Stock (Filed With SEC on June 22, 2020)
License Agreement by and between Kinex Pharmaceuticals, LLC and Guangzhou Xiangxue New Drug Discovery and Development Company Limited, effective as of May 6, 2012 (Filed With SEC on May 7, 2020)
License Agreement by and between Kinex Pharmaceuticals, Inc. and PharmaEssentia Corp., effective as of December 16, 2013 (Filed With SEC on May 7, 2020)
Second Amendment to License Agreement by and between Athenex, Inc. and PharmaEssentia Corp., effective as of November 27, 2018 (Filed With SEC on May 7, 2020)
Description of Securities (Filed With SEC on March 2, 2020)
License Agreement between the Company and Guangzhou Xiangxue Pharmaceutical Co., Ltd. dated December 12, 2019 (Filed With SEC on December 16, 2019)
Form of Registration Rights Agreement (Filed With SEC on December 5, 2019)
Share Purchase Agreement, by and among Athenex, Inc., M. Kingdon Offshore Master Fund, LP, Schonfeld Strategic 460 Fund LLC, Point72 Associates, LLC, J. Goldman Master Fund, L.P.,... (Filed With SEC on December 5, 2019)
Supplemental Agreement to Athenex Pharmaceutical Base Project Located in the Chongqing Maliu Riverside Development Zone Agreement with Chongqing Maliu Riverside Development and... (Filed With SEC on August 7, 2019)
Amendment to Grant Disbursement Agreement by and between the New York State Urban Development Corporation d/b/a Empire State Development and Athenex, Inc (Filed With SEC on August 7, 2019)
Amendment No. 2 to Credit Agreement by and between Athenex, Inc. and Perceptive Advisors LLC, dated as of August 5, 2019 (Filed With SEC on August 7, 2019)
Amendment No. 1 to Credit Agreement by and between Athenex, Inc. and Perceptive Advisors LLC, dated as of April 22, 2019 (Filed With SEC on August 7, 2019)
Second Amendment to License and Development Agreement by and between Athenex, Inc., Almirall, S.A., and Aqua Pharmaceuticals LLC, dated as of June 18, 2019 (Filed With SEC on August 7, 2019)
Second Amendment to Agreement by and between M+W U.S., Inc. and Athenex, Inc., effective as of October 1, 2018 (Filed With SEC on May 9, 2019)
First Amendment to Agreement by and between M+W U.S., Inc. and Athenex, Inc., effective as of March 27, 2018 (Filed With SEC on May 9, 2019)
Share Purchase Agreement, by and among Athenex, Inc., Perceptive Life Sciences Master Fund, Ltd., venBio Select Fund LLC, OrbiMed Partners Master Fund Limited, and The Biotech... (Filed With SEC on May 6, 2019)
Form of Registration Rights Agreement (Filed With SEC on May 6, 2019)
Second Amendment to License Agreement by and between Athenex, Inc. and PharmaEssentia Corp., effective as of November 27, 2018 (Filed With SEC on March 11, 2019)
Fifth Amendment to License Agreement by and between Athenex, Inc. and Hanmi Pharmaceutical Co. Ltd., effective as of September 4, 2018 (Filed With SEC on March 11, 2019)
Mutual Letter of Termination of the License Agreement by and between Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Ltd., effective as of August 20, 2018 (Filed With SEC on March 11, 2019)
License Agreement, dated as of December 30, 2018 by and between Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd (Filed With SEC on January 3, 2019)
Sublicense Agreement, dated as of December 30, 2018 by and among Chongqing Taihao Pharmaceutical Co. Ltd., Chongqing Jingdong Junzhuo Pharmaceutical Co., Ltd., and Athenex, Inc (Filed With SEC on January 3, 2019)